Natasja BROOIJMANS,Lucian V. DIPIETRO,Paul E. FLEMING,Joseph L. KIM,Steven Mark WENGLOWSKY,Yulian ZHANG
申请号：
US16228381
公开号：
US20190359591A1
申请日:
2018.12.20
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity
